12.10 - 13.25
SESSION I – MYELOPROLIFERATIONS
Chairpersons: Dr Olga Grzybowska-Izydorczyk, Dr hab. Tomasz Czerw
12.10 - 12.25
Optimizing JAK inhibitor selection in myelofibrosis
Professor Grzegorz Helbig
12.25 - 12.40
Therapeutic goals in essential thrombocytosis and how to achieve them?
Dr hab. Marta Sobas
12.40 - 12.55
Therapeutic goals for polycythemia vera and how to achieve them?
Professor Joanna Góra-Tybor
12.55 - 13.10
Treatment of advanced phase CML
Professor Tomasz Sacha
13.25 - 13.40
Coffee break
13.40 - 14.40
SESSION II – MDS/PNH
Chairpersons: Dr hab. Agnieszka Pluta, Dr Olga Grzybowska-Izydorczyk
13.40 - 13.55
Low-risk MDS – how do I treat it and will treat it in the coming decade?
Professor Aleksandra Butrym
13.55 - 14.10
High-risk MDS – how to define it and treat it?
Professor Lidia Gil
14.10 - 14.25
PNH – therapy optimization
Professor Anna Szmigielska-Kapłon
15.25 - 16.30
SESSION III – AML
Chairpersons: Professor Jerzy Hołowiecki, Professor Agnieszka Wierzbowska
15.25 - 15.45
Integrating novel therapies in front-line AML (from 3+7 to personalized therapy)
Professor Richard Stone, USA
15.45 - 16.00
MRD in AML – prophylactic or pre-emptive approach?
Professor Agnieszka Wierzbowska
16.00 - 16.15
AZA/VEN Resistance - Houston we have got a problem
Dr hab. Agnieszka Pluta
16.30 - 16.45
Coffee break
16.45 - 17.45
SESSION IV – Modern Therapies in Hemato-Oncology, Part 1
Chairpersons: Professor Agnieszka Wierzbowska, Dr hab. Agnieszka Pluta
16.45 - 17.00
Lecture under the patronage of 
Maintenance treatment for FLT3(+) acute myeloid leukemia, new challenges
Dr Magdalena Czemerska
17.00 - 17.15
Sponsored lecture 
Optimization of AML treatment with VenAza regimen in the context of Polish RWE data
Dr hab. Łukasz Bołkun
17.15 - 17.30
Sponsored lecture 
Long-Term Response to to IDH1 inhibitor – ivosidenib in combination with Azacitidine
Dr hab. Elżbieta Kalicińska
17.30 - 17.45
Sponsored lecture 
Luspatercept in low-risk MDS- for whom? and why?
Dr hab. Agnieszka Pluta
17.45 - 18.00
Coffee break
18.00 - 19.05
Session V – ALL: “In uncharted waters”
Chairpersons: Professor Ewa Lech-Marańda, Dr hab. Tomasz Czerw
18.00 - 18.20
Chemotherapy and allo-HCT for Ph(+) ALL. Has the ship sunk yet?
Professor Hagop Kantarjian, USA
18.20 - 18.35
First-line treatment of patients with Ph(-) ALL. New coordinates.
Professor Anna Czyż
18.35 - 18.50
CAR-T in ALL. Destroyer or tug?
Professor Sebastian Giebel
